ELOXX PHARMACEUTICALS, INC.: financial reference

Context from the filing

Eloxx's 2021 and 2022 share and per-share amounts are retrospectively adjusted for the December 1, 2022 one-for-40 reverse split. The filing excludes potential preferred-stock, option, warrant and restricted-unit shares because they are anti-dilutive. Dollar losses are displayed in thousands, but share counts and per-share data are unscaled. The historical filing's full share counts and reported USD EPS are preserved. Read the source filing.

For 2023–2025, Eloxx’s basic and diluted EPS denominators include both common shares and pre-funded warrants. The filing includes those warrants because their exercise requires only minimal cash and has no substantive contingencies. Other potentially dilutive securities are excluded as anti-dilutive. The denominator is therefore not simply issued common shares. Shares and per-share amounts are exempt from the thousands heading; the reported counts and EPS remain unchanged. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Inspect the source

Entity

ELOXX PHARMACEUTICALS, INC. / CIK 0001035354

Captured

2026-09-20T05:15:09.498Z

SEC response SHA-256

b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))